A company executive at Generic Corp. (NASDAQ:COMPANY) recently reported selling approximately $1.73 million worth of the company’s non-derivative common stock, according to a recent SEC Form 4 filing. The transactions involved both direct sales and sales executed under a pre-arranged plan. The sales come as the stock trades near its 52-week high of $40.43, following a remarkable 122% surge over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, with shares up 116% year-to-date.
The filing indicated sales totaling $549,303 from transactions associated with a footnote, with prices ranging between $36.16 and $37.04 per share. Additionally, the executive sold shares totaling $1,185,186 in other transactions, with prices for these sales ranging from $36.00 to $37.96. The report detailed these transactions of non-derivative securities.
In other recent news, MapLight Therapeutics has been the focus of several analyst updates and corporate developments. The company recently reported top-line results from its Phase 2 IRIS study of ML-004, targeting autism spectrum disorder. This study included 161 participants, with analyses based on age group and baseline irritability severity. Following these results, H.C. Wainwright reiterated a Buy rating and maintained a $45 price target on the stock. Needham also raised its price target for MapLight Therapeutics from $42 to $45, citing increased probability of success for the company’s lead candidate, ML-007-MC, for schizophrenia treatment. Raymond James initiated coverage with a strong buy rating and set a price target of $46, highlighting the positive risk/reward profile ahead of the Phase 2 ZEPHYR readout. Additionally, MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, following the departure of two other board members. These appointments include Babler joining the Audit Committee and Cox serving as Chair of the Nominating and Corporate Governance Committee.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
